trending Market Intelligence /marketintelligence/en/news-insights/trending/xtXlKMTXXISw_kYpWhUTrg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TherapeuticsMD seeks nod for hormone therapy; Immunicum completes rights issue

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


TherapeuticsMD seeks nod for hormone therapy; Immunicum completes rights issue

Top news

* TherapeuticsMD Inc. submitted a new drug application to the U.S. Food and Drug Administration for TX-001HR, a treatment for menopause-related symptoms known as hot flashes. The treatment is a bio-identical hormone therapy combination of estradiol and progesterone.

* Immunicum AB (publ) completed its 90% secured rights issue with preferential rights for existing shareholders, generating proceeds of about 168 million Swedish kronor after transaction costs. The money raised will enable the company to conclude its phase 2 Mereca and phase 1/2 Gist clinical trials for cancer treatment ilixadencel.

M&A and capital markets

* Israel-based BioCancell Ltd.'s shareholders turned down a tender offer to take the company private, Reuters reported.

Operational activity

* Chugai Pharmaceutical Co. Ltd. is planning to invest about ¥25 billion in a Singapore research laboratory for biopharmaceuticals by 2021, looking to expand the development of therapeutic antibodies, Nikkei Asian Review reported. The lab will seek to make antibodies more functional.

Other features

* FierceBiotech has a feature about the possibility of using chimeric antigen receptor T cells, or CAR-T cell therapy, for treating HIV. CAR-T cell therapies have been approved in the U.S. this year to treat specific cancers.

* Side effects might outweigh the positive results for Johnson & Johnson's depression treatment esketamine, Endpoints News reports. The treatment was shown to improve patients' MADRS scores, a measure of the severity of depressive episodes, but caused side effects including perceptual changes and dissociative symptoms.

The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.